Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast

Pliant Therapeutics in the NEWS
Treating Primary Sclerosing Cholangitis 

Pliant Therapeutics (PLRX) today announced positive data from a Phase 2a INTEGRIS-PSC clinical trial of the firm’s product bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis.

PSC is a rare, progressive liver disease of unknown origin, which frequently occurs in the setting of . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.